In 1992, the UICC introduced the additional tumor stage Tic for prostate carcinoma (PCa) because of the increasing proof of nonpalpable prostate carcinomas in patients, which were detected through prostate-specific antigen (PSA) raise only. Initial uncertainties about the clinical value of these nonpalpable tumors could be clarified by extensive investigations. It could be demonstrated that Tic prostate cancers are distinct from latent PCa as found after cystoprostatectomy. Examinations of specimens of Tic PCa after radical prostatectomy showed that these tumors have a clinically relevant tumor volume in 84-94% of the cases. The mean tumor volumes of Tic carcinomas were between 1.67 and 7.4 cm3. Capsular perforations were present in 23-30%, and positive margins were found in 7-34% of cases. These results are comparable with those of clinical stage T2 tumors. Both Tic and T2 prostate carcinomas are, in most cases, restricted to the surgical specimen and, thus, curable. These data show that patients with Tic PCa need curative treatment.

Keywords:
PSA, Prostate carcinoma (indication for treatment), Tumor stage
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.